An experimental personalised mRNA vaccine developed by Merck & Co. and Moderna has reduced the risk of melanoma recurrence and spread in a phase 3 clinical trial, marking the first time an mRNA-based cancer therapy has produced positive late-stage results. The treatment, called intismeran autogene, was tested on 1,137 high-risk patients whose tumours had been surgically removed, administered alongside Merck's immunotherapy drug Keytruda.
The combination therapy significantly improved relapse-free survival compared with Keytruda alone over roughly one year of follow-up. Moderna President Stephen Hoge said thousands of patients could benefit by next year if regulators approve the vaccine. The companies are already in discussions with regulatory agencies and plan to submit marketing applications.
The announcement triggered sharp market moves, with Moderna shares surging over 150 percent and Merck stock rising more than 8 percent in pre-market trading. Full trial data will be presented at an upcoming international medical conference.